Aliskiren for hypertension in adults

Drug and Therapeutics Bulletin

Volumn 46, Issue 10, 2008, Pages 73-76

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; RAMIPRIL; VALSARTAN; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE; RENIN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; HEADACHE; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; ADULT; ARTICLE; DRUG ANTAGONISM; DRUG COMBINATION; HYPERTENSION; TREATMENT OUTCOME;

ADULT; AMIDES; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; RENIN; TREATMENT OUTCOME;

EID: 58149268189     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2008.09.0022     Document Type: Review

References (18)

1. Kearney PM et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
2. Rasilez tablets 150 mg and 300 mg. Summary of product characteristics, EU. Novartis Europharm Limited, August 2007.
3. Danser AHJ. Local renin-angiotensin systems. Mol Cell Biochem 1996; 157: 211-6.
4. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
5. Gradman AH et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-8.
6. Pool JL et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20.
7. Oparil S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-9.
8. Villamil A et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217-26.
9. Kushiro T et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005.
10. Oh BH et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-63.
11. Verdecchia P et al. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure 2007; 16: 381-91.
12. Uresin Y et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-8.
13. Stanton A et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-43.
14. Parving HH et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. New Engl J Med 2008; 358: 2433-46.
15. Jordan J et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047-55.
16. Drummond W et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens 2007; 9: 742-50.
17. Andersen K et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-99.
18. Strasser RH et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007; 21: 780-7.